Klinik Landstrasse

The research program at Klinik Landstrasse emphasizes innovative strategies to lower the risk of heart attacks, strokes, and related complications in patients with cardiovascular disease. Studies compare novel agents to standard care, aiming to improve outcomes for those with high lipid levels, elevated lipoprotein(a), and advanced arterial disease.

• Acute Myocardial Infarction
• Atherosclerotic Cardiovascular Disease
• Elevated Lp(a)
• Left Ventricular Hypertrophy
• Adults at high risk of cardiovascular events without prior MI or stroke

With three dedicated investigators, the site conducts multiple trials to evaluate the safety and effectiveness of emerging cardiovascular therapies, supporting patients at high risk of recurrent events.

Clinical investigations target liver health, focusing on non-alcoholic steatohepatitis (NASH) and broader metabolic dysfunction-associated steatotic liver disease. The goal is to determine whether new treatments can improve liver histology and reduce progression to cirrhosis.

• Metabolic Dysfunction-Associated Steatotic Liver Disease
• Non-alcoholic steatohepatitis (NASH)

The department leverages its expertise in endocrinology and hepatology to advance therapeutic options for patients with fatty liver conditions.

Research at the site addresses the growing burden of obesity, overweight, and type 2 diabetes mellitus. Trials explore weight‑loss agents and glucose‑lowering drugs to achieve better metabolic control and reduce associated health risks.

• Obesity
• Overweight
• Overweight and obesity and type 2 diabetes
• Type 2 Diabetes Mellitus

By testing novel combinations and dose regimens, investigators aim to provide safer, more effective options for metabolic disease management.

The department’s metabolic research includes studies on kidney function and albuminuria, seeking therapies that protect renal health while modulating metabolic pathways.

• Chronic Kidney Disease
• Chronic Kidney Disease and Albuminuria
• Hemodialysis
• Kidney Failure

Through collaborative trials, the site evaluates how metabolic interventions can slow disease progression and improve quality of life for patients with renal impairment.